Lawson M, Cureton N, Ros S, Cheraghchi-Bashi-Astaneh A, et al. The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance. Cancer Res 2023 Sep 19. doi: 10.1158/0008-5472.CAN-23-0694.
PMID: 37725704